Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Oncology

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDH305PMID 15277260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

  2002cited by this paper
• High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

  2001cited by this paper
• Phase II evaluation of an alternated FOLFOX/FOLFIRI regimen in patients with resistant metastatic colorectal cancer (CRC)

  2001cited by this paper
• Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

  1999cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.

  1999cited by this paper
• Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model

  1999cited by this paper
• 933 Oxaliplatin (L-OHP®): Global safety in 682 patients (PTS)

  1995cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Neratinib-loaded solid lipid nanoparticles in dissolvable microneedles for enhanced transdermal breast cancer therapy.

  2025cites this paper
• Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients

  2025cites this paper
• Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method

  2024cites this paper
• Safety outcomes of rapid- versus standard-infusion rate oxaliplatin

  2023cites this paper
• Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study

  2023cites this paper
• Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia

  2022cites this paper
• Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)

  2021cites this paper
• Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study

  2021cites this paper
• Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line?

  2021cites this paper
• Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

  2021cites this paper
• Microbiome in drug resistance to colon cancer.

  2021cites this paper
• Rechallenge Strategy in Cancer Therapy

  2020cites this paper
• Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities.

  2020cites this paper
• Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis

  2020cites this paper
• Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study

  2020cites this paper
• Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)

  2020cites this paper
• Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

  2020cites this paper
• Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity

  2020cites this paper
• Insights into the success and failure of systemic therapy for hepatocellular carcinoma

  2019cites this paper
• Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.

  2019cites this paper
• OXALIPLATIN RE-INTRODUCTION THERAPY AMONG PATIENTS WITH ADVANCE STAGE COLORECTAL CANCER

  2019cites this paper
• Maximising clinical benefit with adequate patient management beyond the second line in mCRC

  2019cites this paper
• The comparison of oxaliplatin or irinotecan rechallenge treatment with regorafenib in the third-line treatment of metastatic colorectal cancer

  2019cites this paper
• Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

  2019cites this paper
• Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

  2019cites this paper
• Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients

  2018cites this paper
• Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

  2018cites this paper
• Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

  2018cites this paper
• Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer

  2018cites this paper
• Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.

  2017cites this paper
• REDEFINING LATER-LINE THERAPY IN METASTATIC COLORECTAL CANCER This symposium took place on 29 th June 2017 as part of the 19 th World Congress on Gastrointestinal Cancer in Barcelona , Spain Chairpersons

  2017cites this paper
• Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

  2017cites this paper
• Redefining Later-Line Therapy in Metastatic Colorectal Cancer

  2017cites this paper
• REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin‐containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single‐center Study

  2017cites this paper
• Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

  2016cites this paper
• Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?

  2015cites this paper
• Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

  2015cites this paper
• The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer

  2015cites this paper
• Multimodality Management of Oligometastatic Colorectal Cancer

  2015cites this paper
• Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

  2014cites this paper
• [Basic evidence for efficacy of Goshajinkigan on oxaliplatin-induced neuropathy].

  2014cites this paper
• Rechallenge With Oxaliplatin and Fluoropyrimidine for Metastatic Colorectal Carcinoma After Prior Therapy

  2013cites this paper
• Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.

  2013cites this paper
• Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.

  2013cites this paper
• Drug rechallenge and treatment beyond progression—implications for drug resistance

  2013cites this paper
• A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors?

  2013cites this paper
• Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer

  2013cites this paper
• Platinum-sensitivity in metastatic colorectal cancer: towards a definition.

  2013cites this paper
• Literature review and practical aspects on the management of oxaliplatin-associated toxicity.

  2012cites this paper
• Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them.

  2012cites this paper
• Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.

  2012cites this paper
• Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer

  2012cites this paper
• Treatment of Liver Metastases

  2011cites this paper
• A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab

  2011cites this paper
• FOLFOX / FOLFIRI 療法下患者の血圧上昇

  2011cites this paper
• Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.

  2010cites this paper
• Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX

  2010cites this paper
• Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX 6 for Metastatic Colorectal Cancer

  2010cites this paper
• A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors

  2010cites this paper
• Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.

  2010cites this paper
• Impact of Resection for Primary Colorectal Cancer on Outcomes in Patients with Synchronous Colorectal Liver Metastases

  2010cites this paper
• Systemic Therapy for Non-operable Colorectal Cancer Metastases

  2009cites this paper
• Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy

  2009cites this paper
• Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis

  2009cites this paper
• Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

  2009cites this paper
• Predictive oncology comes to colorectal cancer

  2009cites this paper
• Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer

  2009cites this paper
• Peripheral sensory neuropathy--fighting cold with cold.

  2008cites this paper
• Oxaliplatin-based chemotherapy in the management of colorectal cancer

  2008cites this paper
• Genetic alterations and sensitivity to anti-cancer drugs in colorectal cancer cells

  2008cites this paper
• Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence

  2008cites this paper
• The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

  2008cites this paper
• Highlights from: The 2008 Gastrointestinal Cancers Symposium; Orlando, FL; January 25-27, 2008

  2008cites this paper
• Colorectal Cancer Update: New Strategies in Supportive Care

  2008cites this paper
• Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

  2008cites this paper
• Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

  2008cites this paper
• Current and emerging trends in the treatment of metastatic colorectal cancer

  2007cites this paper
• FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer

  2007cites this paper
• Factoring drug-free intervals into the management of patients with advanced colorectal cancer

  2007cites this paper
• [Pharmacotherapy of colon cancer].

  2007cites this paper
• Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

  2007cites this paper
• Use of Calcium and Magnesium Salts to Reduce Oxaliplatin-Related Neurotoxicity

  2007cites this paper
• Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.

  2007cites this paper
• Second-line therapy for advanced colorectal cancer.

  2007cites this paper
• Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

  2007cites this paper
• [Angiogenesis targeting in gastro-intestinal cancers].

  2007cites this paper
• Medikamentöse Therapie des Kolonkarzinoms

  2007cites this paper
• OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

  2006cites this paper
• SIR-Spheres for the treatment of non-resectable liver tumours: August 2005 MSAC Application 1082 Assessment report

  2006cites this paper
• Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

  2006cites this paper
• Recent advances in the systemic management of colorectal cancer.

  2006cites this paper
• Metastatic colorectal cancer.

  2006cites this paper
• Glutathione S-Transferase P 1 Polymorphism ( Ile 105 Val ) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

  2006cites this paper
• Optimum use of biologics and role of maintenance therapy in colon cancer.

  2006cites this paper
• Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.

  2006cites this paper
• Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment

  2006cites this paper
• [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].

  2006cites this paper
• Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

  2006cites this paper
• Möglichkeiten der palliativen Therapie des Rektumkarzinoms

  2005cites this paper
• Chemotherapy for Metastatic Rectal Cancer

  2005cites this paper